Events

As the December 1, 2026 release of the revised USP <87>, Biological Reactivity Tests, In Vitro, approaches, pharmaceutical and medical device manufacturers should begin evaluating how these changes may impact their material qualification, biological evaluation, and compliance strategies. While the final chapter has not yet been published, the proposed direction reflects a broader industry shift...

A risk-averse investment climate has made it more difficult for startups to find the funding needed to bring novel treatments into the clinic. However, alternative funding sources, investment models, and nontraditional investors are stepping in to fill the void. Our panel of experts will identify and discuss new funding opportunities and strategies for companies at...

Virtual Pharma Expo - a themed event featuring presentations and demonstrations by leading experts from pharmaceutical equipment providers for oral solid dose manufacturing and packaging.

Innovations in self-administered and wearable drug delivery technologies promise convenience but bring questions about how to effectively monitor and manage patient safety, adherence, dosing accuracy, and, ultimately, medical outcomes. In this live online session, expert panelists will discuss approaches to leveraging the power of digital tools to provide feedback loops and administrative controls. From both...

Transitioning development processes into GMP manufacturing can come with a fair share of growing pains. Development teams need to contend with things like sourcing and validating new materials, ensuring regulatory compliance, performing risk assessments, and evaluating facility fit. Unexpected challenges in any aspect of this transition can be costly and delay a product’s time to...

For cell therapy developers, manufacturing success starts well before a process enters a GMP cleanroom. Decisions around donor and material sourcing, collection strategy, starting material specifications, process development, and analytical strategy can directly influence process consistency, technology transfer, and manufacturing readiness. Join technical experts from New York Blood Center Enterprises’ Comprehensive Cell Solutions (CCS) team...